IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.926
NA - Nord America 1.889
EU - Europa 789
SA - Sud America 167
Continente sconosciuto - Info sul continente non disponibili 110
AF - Africa 31
OC - Oceania 13
Totale 7.925
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.604
US - Stati Uniti d'America 1.786
CN - Cina 682
HK - Hong Kong 369
IT - Italia 312
BR - Brasile 115
GB - Regno Unito 113
FR - Francia 93
DE - Germania 90
VN - Vietnam 60
CZ - Repubblica Ceca 54
BD - Bangladesh 53
IN - India 44
CA - Canada 43
MX - Messico 40
FI - Finlandia 26
NL - Olanda 22
ID - Indonesia 15
AR - Argentina 13
ZA - Sudafrica 13
AU - Australia 12
PL - Polonia 11
ES - Italia 10
UA - Ucraina 10
CO - Colombia 9
JP - Giappone 9
PH - Filippine 9
PK - Pakistan 9
SA - Arabia Saudita 9
PY - Paraguay 8
TR - Turchia 8
CL - Cile 7
MY - Malesia 7
RU - Federazione Russa 7
TW - Taiwan 7
BE - Belgio 6
EC - Ecuador 6
IQ - Iraq 6
CR - Costa Rica 5
JO - Giordania 5
MD - Moldavia 5
PT - Portogallo 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
JM - Giamaica 4
NP - Nepal 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
EE - Estonia 3
GE - Georgia 3
GT - Guatemala 3
IE - Irlanda 3
KR - Corea 3
LT - Lituania 3
SE - Svezia 3
TN - Tunisia 3
AO - Angola 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EG - Egitto 2
MA - Marocco 2
PE - Perù 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RW - Ruanda 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 7.816
Salva come PNG Salva come JPEG
Città #
San Jose 561
Singapore 408
Hong Kong 367
Ashburn 312
Rome 230
Beijing 210
Hefei 184
Council Bluffs 130
Boardman 106
Columbus 100
London 83
Lauterbourg 79
Dallas 68
Shanghai 61
Santa Clara 60
Munich 48
Los Angeles 36
Brno 35
Mexico City 26
San Francisco 26
New York 23
Pune 20
Redmond 20
Ho Chi Minh City 19
Amsterdam 18
Olomouc 17
São Paulo 16
Hanoi 14
Turku 14
Seattle 13
Guangzhou 12
Helsinki 11
Toronto 11
Washington 11
Manchester 10
Boston 9
Montreal 8
Nuremberg 8
Orem 8
Tokyo 8
Warsaw 8
Brooklyn 7
Chicago 6
Melbourne 6
Rio de Janeiro 6
Campinas 5
Chennai 5
Frankfurt am Main 5
Haiphong 5
Hangzhou 5
Johannesburg 5
Kuala Lumpur 5
Palermo 5
Riyadh 5
San José 5
Amman 4
Ankara 4
Atlanta 4
Biên Hòa 4
Caracas 4
Dhaka 4
Haikou 4
Milan 4
Paris 4
Phoenix 4
Taipei 4
Tashkent 4
Wuhan 4
Alessandria 3
Brasília 3
Buenos Aires 3
Canberra 3
Colombo 3
Dublin 3
Genoa 3
Hanover 3
Hyderabad 3
Jakarta 3
Karachi 3
Las Vegas 3
Mol 3
New Delhi 3
Oklahoma City 3
Philadelphia 3
Quito 3
Stockholm 3
Sydney 3
Tbilisi 3
The Dalles 3
Tirana 3
Xiamen 3
Asunción 2
Aversa 2
Berlin 2
Bismarck 2
Bogotá 2
Buffalo 2
Cairo 2
Changsha 2
Concord 2
Totale 3.622
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 234
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 228
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 208
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 208
Cancer drugs and QT prolongation: weighing risk against benefit 207
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 207
Minimal sampling colistin pharmacokinetics in critically ill patients 204
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 202
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 197
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 195
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 194
Cardio-oncology in clinical studies and real life 185
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 182
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 180
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 158
Anthracycline Cardiotoxicity 141
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 140
Anthracyclines 127
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 126
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 125
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 125
Anthracycline Cardiotoxicity 115
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 107
An introduction to the metabolic determinants of anthracycline cardiotoxicity 105
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 101
Cardiotoxicity of antitumor drugs 101
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 97
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 93
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 90
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 89
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 79
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 72
Isavuconazole: case report and pharmacokinetic considerations 71
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 68
Pharmacology of Cardio-Oncology 68
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 67
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 67
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 67
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 66
What is cardiotoxicity? 64
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 64
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 63
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 62
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 62
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 62
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 62
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 62
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 60
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 59
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 59
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 58
Pharmacological Foundation of Cardio-Oncology 57
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 57
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 56
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 55
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 55
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 52
The concomitant management of cancer therapy and cardiac therapy 51
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 51
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 48
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 46
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 46
Doxorubicin degradation in cardiomyocytes 45
Matters of the heart: The case of TNF-alpha targeting drugs 45
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 45
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 44
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 44
Molecular determinants of the reduced cardiotoxicity of epirubicin 44
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 43
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 43
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 43
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 43
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 42
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 42
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 42
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 41
The reality of pixantrone in real life 41
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 41
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 41
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 41
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 40
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 40
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 38
In ®Entresto we trust 38
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 38
Translating molecular mechanisms into clinical facts 38
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 38
Humans and Rodents: The Case of hOAT4 and mOat5 37
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 37
Do you know pixantrone? 36
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 35
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 33
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 32
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 31
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 9
Indications for the harmonization of the therapeutic ranges for antifungal agents 7
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 7
Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies 7
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? 4
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 7.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.224
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20262.976 336 204 131 250 139 94 923 205 219 257 106 112
2026/2027299 74 225 0 0 0 0 0 0 0 0 0 0
Totale 7.925